-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
IQVIA reported Q1 2026 revenue of $4,151M (+8.4% Y/Y), led by robust Commercial Solutions growth (+11.6% Y/Y) and steady R&D Solutions performance (+6.2% Y/Y). Adjusted EPS of $2.90 (+7.4% Y/Y) exceeded guidance and beat consensus by $0.08. R&D Solutions bookings were encouraging, in our view, with net new bookings of $2.5B generating a book-to-bill ratio of 1.04x amid what management described as a stabilizing biopharmaceutical market. IQV raised 2026 adjusted EPS guidance to $12.65-$12.95 (up $0.10 at the midpoint) while reaffirming revenue and EBITDA guidance. The contracted backlog of $34.2B supports revenue visibility, with $8.9B expected to convert over the next twelve months (+7.6% Y/Y), though EBITDA margin declined to 22.5% from 23.1%. We view mid-to-high single digit growth in forward-looking demand indicators as suggesting continued client momentum, while the company maintained flexibility with $552M in share repurchases and 15% FCF growth to $491M.